Major biopharma companies, including Genentech and Gilead, are using AI models to find new medicines, optimize trial designs, and boost manufacturing efficiency.

We're featured alongside them in this ITIF report, which touches on some AI tools we're building for gene therapies.

The F.D.A. recently approved Aucatzyl, a CD19 CAR-T therapy for B-ALL leukemia in adults. It joins a handful of other approved CAR-T therapies designed to treat various forms of cancers, including multiple myeloma. But it’s worth looking at Aucatzyl, in particular, because it has a unique aspect. 1/

We built a codon optimizer that boosts expression of clinically-relevant transgenes up to 7x. We’ve compared our algorithm to five other codon optimizers available on the market, and results suggest that our algorithm is consistently superior across genes of interest.

So why does this matter?

We built a codon optimizer that boosts expression of clinically-relevant transgenes up to 7x. We’ve compared our algorithm to five other codon optimizers available on the market, and results suggest that our algorithm is consistently superior across genes of interest.

So why does this matter?